Deals In Depth: September 2013
Biogen and Isis teamed up for the fourth time in a new deal worth $450 million, focused on CNS disorders; Stryker gained robotic-assisted surgery expertise in its $1.4 billion acquisition of MAKO Surgical. Biopharma financing more than doubled in September compared with the previous month, reaching $1.7 billion and boosted by KV Pharma’s $375 million offering; device fundraising also increased, to $205 million, driven by early-stage venture rounds.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.